On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...